IceCure Medical Ltd. announced that it expects to report record fourth quarter sales in North America, driven by the recent FDA clearance of its ProSense® cryoablation system for the treatment of low-risk breast cancer in women aged 70 and above. The company reported that ProSense® systems are being sold and installed at new locations across North America, including several highly regarded medical institutions in the United States. IceCure stated that the FDA's marketing authorization has acted as a major catalyst for growth in its sales pipeline. The company plans to release preliminary top-line revenue results in January 2026, followed by its full annual report on Form 20-F in April 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO49676) on December 17, 2025, and is solely responsible for the information contained therein.